Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-08-26 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2020年半年度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (420 characters) from Shenzhen BGI Genomics Co., Ltd. It states that the company's 2020 semi-annual report (half-year report) has been approved and published on a public website. The text does not contain the actual financial data or detailed report content but rather informs investors about the availability of the report. According to the 'MENU VS MEAL' rule, such a brief notice that a report has been published and is available elsewhere should be classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2020-08-26 Chinese
关于海外新型冠状病毒检测相关媒体报道的说明公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. addressing media reports about their COVID-19 testing kits. It clarifies product qualifications, addresses concerns about high positive detection rates, and discusses risks related to COVID-19 business and overseas operations. The document does not contain financial statements, earnings data, or detailed management analysis. It is a regulatory announcement clarifying media reports and providing risk disclosures, typical of a Regulatory Filings (RNS) category. The document length is short (2109 characters) and it is not a report itself but an explanatory announcement.
2020-08-26 Chinese
关于与上海润达医疗科技股份有限公司签署战略合作协议的公告
Capital/Financing Update Classification · 90% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. about signing a strategic cooperation agreement with Shanghai Runda Medical Technology Co., Ltd. It details the nature of the agreement, the parties involved, the cooperation content, and the impact on the company. The document explicitly states that the agreement is a framework and does not involve specific projects or amounts, and it does not require board or shareholder approval. It also discusses shareholder shareholding changes and risk warnings related to the cooperation. There are no financial statements or detailed financial performance data presented, nor is this a transcript, audit report, or regulatory filing of a financial report. The document is a formal announcement of a strategic cooperation agreement, which fits best under the category of Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes, or strategic partnership announcements. However, since the cooperation agreement is a strategic partnership and not a direct financing or capital structure change, and given the absence of direct financing or capital structure details, the best fitting category is Capital/Financing Update (CAP) because it involves strategic cooperation that may impact company operations and future capital activities. Confidence is high due to the clear nature of the document as a strategic cooperation announcement and the absence of other more fitting categories.
2020-08-21 Chinese
关于控股子公司涉诉事项的说明公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding a litigation matter involving its subsidiaries. It details the parties involved, the nature of the lawsuit (patent infringement), the current status of the case, potential impacts on profits, and risk disclosures. There are no financial statements or detailed financial data presented. The document serves as a legal proceedings update rather than a full audit or annual report. It is not a certification or a brief notice of report publication. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 3125 characters, which is sufficient for a substantive announcement but not a full financial report.
2020-08-18 Chinese
关于持股5%以上股东减持股份比例达到1%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a shareholder holding more than 5% reducing their shareholding by more than 1%. It details the shareholder's identity, the number of shares reduced, the percentage of total shares, the method of reduction, and compliance with prior disclosed plans. It includes specific dates and shareholding percentages before and after the reduction. This type of document is a notification of a major shareholding change, specifically a reduction crossing a threshold. It is not a financial report, earnings release, or management report. It is not a proxy, AGM material, or legal proceeding. The document fits the definition of 'Major Shareholding Notification' (MRQ). The document length is 2756 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the correct classification is MRQ with high confidence.
2020-07-21 Chinese
关于子公司被美国商务部列入实体清单的说明公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding the inclusion of its subsidiary in the U.S. Department of Commerce's Entity List. It explains the situation, potential impacts, and the company's response. The document is short (1235 characters), does not contain financial statements or detailed financial data, nor does it present a report or results. It is an informational announcement about a regulatory and geopolitical issue affecting the company, not a financial report or management update. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other categories.
2020-07-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.